Core Insights - Intuitive Surgical (ISRG) is experiencing significant growth driven by its da Vinci surgical systems, with a recurring revenue model that accounted for 81% of overall revenue in Q4 [1] - The company reported a 21% year-over-year revenue increase to $10.06 billion in 2025, alongside a 22.6% rise in net income [2] - The da Vinci system allows for minimally invasive surgeries, leading to better patient outcomes and faster recovery [3] Revenue and Growth - Recurring revenue from instruments, accessories, and services is a key component of Intuitive's financial success, with management expecting da Vinci procedures to grow by 13% to 15% in 2026 [1][6] - The installed base of da Vinci systems increased to 11,106 in 2025 from 9,902 in 2024, with over 3.1 million procedures performed using these systems in 2025 [2] Competitive Advantage - Intuitive Surgical has established a strong competitive moat in the robotic surgery market, supported by high switching costs and long-term relationships with hospitals [6] - The company benefits from hospitals upgrading existing systems, ensuring sustained revenue growth [6] Market Position and Future Outlook - The minimally invasive robotic surgery market is still in its early stages, providing a long runway for growth beyond 2026 [7] - ISRG stock is currently viewed as a strong candidate for durable growth, despite a 19.5% decline year-to-date [3][7] Analyst Consensus - The consensus rating for ISRG stock is "Moderate Buy," with 20 out of 30 analysts recommending a "Strong Buy" and an average target price of $619.85, indicating a 37% upside potential [8]